Pacific Growth Initiates Coverage on Aradigm (ARDM) with a Buy
More News related to ARDM
- Aradigm Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic Fibrosis Patients at the 32nd European Cystic Fibrosis Conference
- Aradigm Presents Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis at 2009 International Conference of the American Thoracic Society
- Aradigm Announces First Quarter 2009 Financial Results
- Piper Jaffray Initiates Aradigm Corporation (ARDM) with a Buy
- Pacific Growth Initiates Coverage on Aradigm (ARDM) with a Buy
Pacific Growth initiates coverage on Aradigm (OTC: ARDM) with a Buy.
Aradigm Corporation is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists.
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
